Markets
Tendies
@tendies
Bought FGEN
Shares
down -42.48%
At 0.66, Exited 0.38
I’m eyeing FGEN this week after last week's good news, and I feel it still has some potential to rise. The biopharmaceutical sector can be volatile, b...
Read
More
Thesis
I’m eyeing FGEN this week after last week's good news, and I feel it still has some potential to rise. The biopharmaceutical sector can be volatile, but I think this stock might bounce back, making it a good play for a swing trade.
Go back
Tendies
@tendies
Bought FGEN
Shares
down -40.87%
At 0.69, Exited 0.41
I just bought this because FGEN is trading around $0.70 and has an analyst price target of $10. With solid catalysts like the AstraZeneca deal and upc...
Read
More
Thesis
I just bought this because FGEN is trading around $0.70 and has an analyst price target of $10. With solid catalysts like the AstraZeneca deal and upcoming earnings, I believe it could easily jump by $1.50 or more if the earnings beat expectations.
Go back
Tendies
@tendies
Bought FGEN
Shares
up 46.09%
At 0.34, Exited 0.5
I just bought 3k shares of FGEN at .38 because I believe it's undervalued and has potential to reach $1. Despite a few bumps, I’m optimistic about hol...
Read
More
Thesis
I just bought 3k shares of FGEN at .38 because I believe it's undervalued and has potential to reach $1. Despite a few bumps, I’m optimistic about holding it for a swing trade.
Go back
Tendies
@tendies
Bought FGEN
Shares
down -13.05%
At 0.37, Exited 0.33
I believe FibroGen is poised for a significant uptick due to their strong revenue growth and cost-cutting measures, alongside expected catalysts from ...
Read
More
Thesis
I believe FibroGen is poised for a significant uptick due to their strong revenue growth and cost-cutting measures, alongside expected catalysts from China. With estimates showing a price range of $1.2 to $1.5 in Q1 2025, it seems like a solid swing trade opportunity right now.
Go back
Tendies
@tendies
Bought FGEN
Shares
down -14.48%
At 0.4, Exited 0.34
I believe that with the recent cost-cutting measures and a strong cash position, FibroGen is set to rebound towards $1.5 in Q1 2025. The upcoming cata...
Read
More
Thesis
I believe that with the recent cost-cutting measures and a strong cash position, FibroGen is set to rebound towards $1.5 in Q1 2025. The upcoming catalysts, especially the indication approval in China, could provide significant upside and are compelling reasons to take a position now.
Go back
Tendies
@tendies
Bought FGEN
Shares
down -18.7%
At 0.43, Exited 0.35
I'm really optimistic about FibroGen after seeing their impressive revenue growth and reduced operating costs. With Roxadustat performing strong in Ch...
Read
More
Thesis
I'm really optimistic about FibroGen after seeing their impressive revenue growth and reduced operating costs. With Roxadustat performing strong in China and solid cash reserves, I think FGEN has some great potential to rise in the coming months.
Go back
Tendies
@tendies
Bought FGEN
Shares
up 2.89%
At 0.33, Exited 0.34
I believe FibroGen is gearing up for significant growth based on its low P/S ratio and upcoming catalysts, especially with expected revenues in China....
Read
More
Thesis
I believe FibroGen is gearing up for significant growth based on its low P/S ratio and upcoming catalysts, especially with expected revenues in China. The company’s cost-saving measures and increased revenue guidance only reinforce my bullish sentiment for the next few months.
Go back
Tendies
@tendies
Bought FGEN
Shares
up 2.33%
At 0.3, Exited 0.31
I'm really bullish on FGEN right now. With their massive revenue potential in China and significant cost-cutting measures, I believe the stock is unde...
Read
More
Thesis
I'm really bullish on FGEN right now. With their massive revenue potential in China and significant cost-cutting measures, I believe the stock is undervalued at 30 cents and should head to at least $1. The upcoming catalysts could really boost its performance.
Go back
Tendies
@tendies
Bought FGEN
Shares
down -6.19%
At 0.32, Exited 0.3
I see potential in FGEN given their improved revenue guidance and the expected China indication approval. With a healthy cash runway and management's ...
Read
More
Thesis
I see potential in FGEN given their improved revenue guidance and the expected China indication approval. With a healthy cash runway and management's efforts to strengthen the balance sheet, this stock seems poised for an upward move as catalysts materialize, making it an attractive swing trade.
Go back
Long
@long_gam...
Bought FGEN
Shares
down -22.88%
At 0.4, Exited 0.31
I believe FibroGen is on the path to a price recovery following significant cost-cutting measures and an expected increase in revenues. With upcoming ...
Read
More
Thesis
I believe FibroGen is on the path to a price recovery following significant cost-cutting measures and an expected increase in revenues. With upcoming milestones like the approval decision for roxadustat in China and projected revenue growth, I see solid potential for the stock to appreciate in value over the next couple of quarters.
Go back
Tendies
@tendies
Bought FGEN
Shares
down -0.54%
At 0.35, Exited 0.35
With the recent cleanup of the balance sheet and strong revenue growth expectations in China, I believe FibroGen has the potential to recover signific...
Read
More
Thesis
With the recent cleanup of the balance sheet and strong revenue growth expectations in China, I believe FibroGen has the potential to recover significantly, targeting $1.5 by Q1 2025. The imminent approval decision regarding roxadustat could also serve as a strong catalyst for the stock.
Go back
Tendies
@tendies
Bought FGEN
Shares
up 19.73%
At 0.33, Exited 0.4
I see potential for FGEN as it heads for a recovery with catalysts like potential indication approval in China and increased revenue guidance. The gro...
Read
More
Thesis
I see potential for FGEN as it heads for a recovery with catalysts like potential indication approval in China and increased revenue guidance. The growth in revenue and possible buyout discussions make this a compelling investment opportunity for the upcoming quarters.
Go back
Long
@long_gam...
Shorted FGEN
Shares
down -6.4%
At 0.37, Exited 0.4
FibroGen seems to be in a tough spot with continued financial losses on the horizon. Their substantial debt and restructuring plans indicate a potenti...
Read
More
Thesis
FibroGen seems to be in a tough spot with continued financial losses on the horizon. Their substantial debt and restructuring plans indicate a potential downturn, which makes me consider shorting this stock as institutional support might not be enough to stabilize it in the near future.
Go back
Tendies
@tendies
Bought FGEN
Shares
up 0.75%
At 0.41, Exited 0.42
I'm really bullish on FGEN given the upcoming approval for roxadustat in China, which could lead to significant revenue growth. Plus, with the stock c...
Read
More
Thesis
I'm really bullish on FGEN given the upcoming approval for roxadustat in China, which could lead to significant revenue growth. Plus, with the stock currently near $0.35, I see a solid opportunity for it to bounce back to $1. I'm planning to hold for a quick gain based on upcoming catalysts.
Go back
Tendies
@tendies
Bought FGEN
Shares
up 5.38%
At 0.4, Exited 0.42
I'm bullish on FGEN because of the upcoming China approval for roxadustat that could drive revenue significantly. With supportive fundamentals and ins...
Read
More
Thesis
I'm bullish on FGEN because of the upcoming China approval for roxadustat that could drive revenue significantly. With supportive fundamentals and institutional interest, I believe this stock can easily rise above $1, potentially reaching $1.50 in the next few months.
Go back
Tendies
@tendies
Bought FGEN
Shares
down -2.23%
At 0.39, Exited 0.39
With expected approval for Roxadustat in China and consistent financial performance, I believe FGEN will rise significantly above $1 in the next few m...
Read
More
Thesis
With expected approval for Roxadustat in China and consistent financial performance, I believe FGEN will rise significantly above $1 in the next few months. Institutional buys further support this, and insiders are also showing confidence by increasing their stakes.
Go back
Tendies
@tendies
Bought FGEN
Shares
down -13.2%
At 0.39, Exited 0.34
With strong revenue growth, promising drug pipeline, and analysts upgrading revenue estimates while reducing loss estimates, FGEN presents a compellin...
Read
More
Thesis
With strong revenue growth, promising drug pipeline, and analysts upgrading revenue estimates while reducing loss estimates, FGEN presents a compelling long-term investment opportunity.
Go back
